NovoCure

NovoCure

NVCR· Manufacturing· Fiscal year ends in December

CEO pay in FY2025Stock -56.6% in FY2025

Frank Leonard is the CEO of NovoCure and was paid $7.0M in FY2025 (Dec), up 20%.

Pay$100 in the stock at the end of FY22 → $18
CEO pay is from each NovoCure proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Executives6

See all
  1. 1Ashley CordovaFY2025
  2. 2Frank LeonardFY2025
  3. 3Christoph BrackmannFY2025
  4. 4Uri WeinbergFY2025
  5. 5Nicholas LeupinFY2025
  6. 6Michael PuriFY2025

Named executives and their total pay, from the Summary Compensation Table of the latest proxy.

Pay

See all

NovoCure paid its 6 named executives $36.4M in total in FY2025 (Dec). CEO Frank Leonard was paid $7.0M of that.

Name
Ashley CordovaFormer Chief Executive Officer
Frank LeonardChief Executive Officer
Christoph BrackmannChief Financial OfficerNot disclosedNot disclosed
Uri WeinbergChief Medical and Innovation OfficerNot disclosed
Nicholas LeupinFormer Chief Medical OfficerNot disclosedNot disclosed
Michael PuriChief Human Resources OfficerNot disclosedNot disclosed

of each named executive, from the Summary Compensation Table of each proxy.

Peers17

See all

The FY2025 (Dec) proxy of NovoCure names 17 peer companies for pay. Pay versus performance data of NovoCure for that year is not on file, so it has no rank.

The comes from the company's proxy. CEO pay and of each company come from its own Pay versus Performance table for the same fiscal year.

Board10

See all
  • Kinyip Gabriel LeungDirector · 14 yr on the boardIndependentNominating and Corporate Governance—Paid as an executive
  • Asaf DanzigerDirector · 13 yr on the boardNot independent—Paid as an executive
  • David Hung, M.D.Director · 7 yr on the boardIndependentNominating and Corporate Governance—Paid as an executive
  • Jeryl HillemanDirector · 7 yr on the boardIndependentAudit—Paid as an executive
  • Allyson OceanDirector · 2 yr on the boardIndependentNominating and Corporate Governance—Paid as an executive
  • Kristin StaffordDirector · 2 yr on the boardIndependentCompensation—Paid as an executive

The board of the latest proxy (FY2025).

Activity

  1. Pay
    NovoCure Division head pay fell 18% to $4.2M. The stock fell 57% in FY2025 (Dec).
    DEF 14A
  2. Pay
    NovoCure CEO pay rose 20% to $7.0M. The stock fell 57% in FY2025 (Dec).
    DEF 14A
  3. Pay
    NovoCure CEO pay rose 16% to $5.8M. The stock rose 100% in FY2024 (Dec).
    DEF 14A
  4. Pay
    NovoCure Former CEO pay rose 117% to $13.2M. The stock fell 57% in FY2025 (Dec).
    DEF 14A
  5. Pay
    NovoCure Division head pay rose 16% to $5.8M. The stock rose 100% in FY2024 (Dec).
    DEF 14A
  6. Pay
    NovoCure Former CEO pay rose 25% to $6.8M. The stock fell 2% in FY2022 (Dec).
    DEF 14A
  7. Pay
    NovoCure Director pay rose 96% to $2.3M. The stock fell 2% in FY2022 (Dec).
    DEF 14A
  8. Pay
    NovoCure Division head pay fell 18% to $5.2M. The stock fell 80% in FY2023 (Dec).
    DEF 14A
  9. Pay
    NovoCure Division head pay rose 15% to $6.3M. The stock fell 2% in FY2022 (Dec).
    DEF 14A
  10. Pay
    NovoCure Division head pay fell 18% to $5.0M. The stock fell 80% in FY2023 (Dec).
    DEF 14A
  11. Board
    Kristin Stafford joined the board of NovoCure. Kristin Stafford sits on no other public board.
    3
  12. Board
    Allyson Ocean joined the board of NovoCure. Allyson Ocean sits on no other public board.
    3

Filings6

See all
Proxy statementDEF 14AApr 20, 2026FY2025
Annual report10-KFeb 26, 2026FY2025
Proxy statementDEF 14AApr 21, 2025FY2024
Annual report10-KFeb 27, 2025FY2024
Proxy statementDEF 14AApr 22, 2024FY2023
Annual report10-KFeb 22, 2024FY2023
For the press:Download CSVDownload PNGHow to use our data